| RS2066382876 |
CASK
|
Health Risk |
Pathogenic |
FG syndrome 4, FG syndrome 4 |
| RS2066399731 |
MITF
|
Health Risk |
Pathogenic |
Melanoma, cutaneous malignant |
| RS2066399994 |
MITF
|
Health Risk |
Conflicting classifications of pathogenicity |
Tietz syndrome, Waardenburg syndrome type 2A |
| RS2066400236 |
MITF
|
Health Risk |
Pathogenic |
Waardenburg syndrome type 2A, Waardenburg syndrome type 2A |
| RS2066400330 |
MITF
|
Health Risk |
Pathogenic |
Waardenburg syndrome type 2A, Waardenburg syndrome type 2A |
| RS2066406973 |
NHS
|
Health Risk |
Pathogenic |
Nance-Horan syndrome, Nance-Horan syndrome |
| RS2066412135 |
MYRF
|
Health Risk |
Pathogenic |
— |
| RS2066424636 |
COL4A5
|
Health Risk |
Likely pathogenic |
X-linked Alport syndrome, X-linked Alport syndrome |
| RS2066425550 |
COL4A5
|
Health Risk |
Conflicting classifications of pathogenicity |
X-linked Alport syndrome, X-linked Alport syndrome |
| RS2066425897 |
COL4A5
|
Health Risk |
Likely pathogenic |
X-linked Alport syndrome, X-linked Alport syndrome |
| RS2066428351 |
COL4A5
|
Health Risk |
Likely pathogenic |
Alport syndrome, Alport syndrome |
| RS2066435557 |
COL4A5
|
Health Risk |
Likely pathogenic |
X-linked Alport syndrome, Thyroid cancer |
| RS2066444344 |
NHS
|
Health Risk |
Pathogenic |
Nance-Horan syndrome, Nance-Horan syndrome |
| RS2066444872 |
TCTN1
|
Health Risk |
Likely pathogenic |
Joubert syndrome, Meckel-Gruber syndrome |
| RS2066445430 |
MYRF
|
Health Risk |
Likely pathogenic |
Congenital diaphragmatic hernia, Heart |
| RS2066454000 |
NHS
|
Health Risk |
Pathogenic |
Nance-Horan syndrome, Nance-Horan syndrome |
| RS2066456693 |
MAG
|
Health Risk |
Pathogenic |
Hereditary spastic paraplegia 75, Hereditary spastic paraplegia 75 |
| RS2066464 |
MTHFR
|
Health Risk |
Conflicting classifications of pathogenicity |
Homocystinuria due to methylene tetrahydrofolate reductase deficiency, MTHFR-related disorder |
| RS2066464113 |
NHS
|
Health Risk |
Pathogenic |
— |
| RS2066466759 |
NF2
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 2 |
| RS2066471565 |
ACO2
|
Health Risk |
Pathogenic |
— |
| RS2066476390 |
MYRF
|
Health Risk |
Conflicting classifications of pathogenicity |
Congenital diaphragmatic hernia, Heart |
| RS2066476444 |
MYRF
|
Health Risk |
Pathogenic |
Inborn genetic diseases, Inborn genetic diseases |
| RS2066476573 |
MYRF
|
Health Risk |
Likely pathogenic |
Cardiac-urogenital syndrome, Cardiac-urogenital syndrome |
| RS2066482511 |
MITF
|
Health Risk |
Pathogenic |
— |
| RS2066482593 |
MITF
|
Health Risk |
Pathogenic |
Waardenburg syndrome type 2A, Tietz syndrome |
| RS2066485367 |
ACO2
|
Health Risk |
Likely pathogenic |
— |
| RS2066505057 |
MYRF
|
Health Risk |
Pathogenic |
Inborn genetic diseases, Inborn genetic diseases |
| RS2066505220 |
NF1
|
Health Risk |
Pathogenic |
Intellectual disability, Intellectual disability |
| RS2066505718 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2066505751 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066506904 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066506934 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Cardiovascular phenotype, Hereditary cancer-predisposing syndrome |
| RS2066507116 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066507272 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2066507556 |
NF1
|
Health Risk |
Pathogenic/Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2066507887 |
NF1
|
Health Risk |
Pathogenic |
— |
| RS2066508210 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2066508538 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066508712 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066509100 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066509240 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066509487 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066510244 |
NF1
|
Health Risk |
Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2066510391 |
NF1
|
Health Risk |
Pathogenic/Likely pathogenic |
Hereditary cancer-predisposing syndrome, Cardiovascular phenotype |
| RS2066510417 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2066510443 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066512609 |
ACO2
|
Health Risk |
Pathogenic/Likely pathogenic |
Optic neuropathy, Optic neuropathy |
| RS2066514 |
SMARCAL1
|
Health Risk |
Conflicting classifications of pathogenicity |
Schimke immuno-osseous dysplasia, SMARCAL1-related disorder |
| RS2066517 |
SMARCAL1
|
Health Risk |
Conflicting classifications of pathogenicity |
Schimke immuno-osseous dysplasia, Schimke immuno-osseous dysplasia |
| RS2066519027 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066519077 |
PCCA
|
Health Risk |
Likely pathogenic |
Propionic acidemia, Propionic acidemia |
| RS2066519253 |
NF1
|
Health Risk |
Pathogenic |
— |
| RS2066519362 |
MAG
|
Health Risk |
Pathogenic/Likely pathogenic |
Hereditary spastic paraplegia 75, Hereditary spastic paraplegia 75 |
| RS2066519416 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066519656 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066519692 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066519817 |
NF1
|
Health Risk |
Pathogenic |
Hereditary cancer-predisposing syndrome, Cardiovascular phenotype |
| RS2066520 |
SMARCAL1
|
Health Risk |
Conflicting classifications of pathogenicity |
Schimke immuno-osseous dysplasia, Kidney disorder |
| RS2066520145 |
NF1
|
Health Risk |
Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2066520848 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066522265 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2066527385 |
NF1
|
Health Risk |
Likely pathogenic |
— |
| RS2066527734 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066527837 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2066528020 |
COL4A5
|
Health Risk |
Likely pathogenic |
Alport syndrome, Alport syndrome |
| RS2066528136 |
MYRF
|
Health Risk |
Pathogenic |
Cardiac-urogenital syndrome, Disorder of sexual differentiation |
| RS2066528976 |
NF1
|
Health Risk |
Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2066529461 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2066529521 |
NF1
|
Health Risk |
Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2066529931 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2066532 |
FMO3
|
Health Risk |
Conflicting classifications of pathogenicity |
Trimethylaminuria, Colon adenocarcinoma |
| RS2066538446 |
ACO2
|
Health Risk |
Pathogenic |
Infantile cerebellar-retinal degeneration, Infantile cerebellar-retinal degeneration |
| RS2066542728 |
COL4A5
|
Health Risk |
Pathogenic |
Alport syndrome, Alport syndrome |
| RS2066559023 |
CASK
|
Health Risk |
Likely pathogenic |
Intellectual disability, Intellectual disability |
| RS2066568818 |
COL4A5
|
Health Risk |
Pathogenic |
Focal segmental glomerulosclerosis, X-linked Alport syndrome |
| RS2066570950 |
ACO2
|
Health Risk |
Pathogenic |
— |
| RS2066578388 |
HLCS
|
Health Risk |
Pathogenic |
Holocarboxylase synthetase deficiency, Holocarboxylase synthetase deficiency |
| RS2066579666 |
TCTN1
|
Health Risk |
Pathogenic |
Meckel-Gruber syndrome, Joubert syndrome |
| RS2066580454 |
NF2
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 2 |
| RS2066581489 |
NF2
|
Health Risk |
Pathogenic |
Familial meningioma, Familial meningioma |
| RS2066587912 |
HLCS
|
Health Risk |
Likely pathogenic |
Holocarboxylase synthetase deficiency, Holocarboxylase synthetase deficiency |
| RS2066594367 |
ACO2
|
Health Risk |
Pathogenic |
Infantile cerebellar-retinal degeneration, Infantile cerebellar-retinal degeneration |
| RS2066618684 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066618707 |
NF1
|
Health Risk |
Pathogenic/Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2066618784 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066619128 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066619428 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066619565 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066621144 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066621213 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066621671 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066622088 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066625021 |
COL4A5
|
Health Risk |
Pathogenic/Likely pathogenic |
X-linked Alport syndrome, X-linked Alport syndrome |
| RS2066625376 |
COL4A5
|
Health Risk |
Conflicting classifications of pathogenicity |
X-linked Alport syndrome, X-linked Alport syndrome |
| RS2066626118 |
COL4A5
|
Health Risk |
Pathogenic |
— |
| RS2066627184 |
COL4A5
|
Health Risk |
Pathogenic |
X-linked Alport syndrome, X-linked Alport syndrome |
| RS2066627294 |
COL4A5
|
Health Risk |
Pathogenic |
— |
| RS2066636714 |
COL4A5
|
Health Risk |
Pathogenic/Likely pathogenic |
Alport syndrome, X-linked Alport syndrome |
| RS2066638829 |
ACO2
|
Health Risk |
Conflicting classifications of pathogenicity |
Optic atrophy 9, Optic atrophy 9 |